Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ANAB | AnaptysBio Inc

Index	RUT	P/E	-	EPS (ttm)	-5.19	Insider Own	12.29%	Shs Outstand	28.51M	Perf Week	-2.10%
Market Cap	481.88M	Forward P/E	-	EPS next Y	-6.80	Insider Trans	-0.43%	Shs Float	23.28M	Perf Month	-9.48%
Income	-144.01M	PEG	-	EPS next Q	-1.78	Inst Own	102.13%	Short Float / Ratio	19.92% / 17.77	Perf Quarter	-11.42%
Sales	12.94M	P/S	37.24	EPS this Y	-48.29%	Inst Trans	4.54%	Short Interest	4.64M	Perf Half Y	-17.12%
Book/sh	5.60	P/B	3.24	EPS next Y	-0.33%	ROA	-25.70%	Target Price	32.00	Perf Year	-28.57%
Cash/sh	16.18	P/C	1.12	EPS next 5Y	-	ROE	-63.62%	52W Range	16.51 - 32.44	Perf YTD	-41.43%
Dividend	-	P/FCF	-	EPS past 5Y	-24.63%	ROI	-30.29%	52W High	-44.04%	Beta	-0.12
Dividend %	-	Quick Ratio	10.53	Sales past 5Y	149.60%	Gross Margin	81.67%	52W Low	9.93%	ATR	0.79
Employees	96	Current Ratio	10.53	Sales Q/Q	184.54%	Oper. Margin	-1083.49%	RSI (14)	42.32	Volatility	4.91% 4.04%
Optionable	Yes	Debt/Eq	2.21	EPS Q/Q	-29.64%	Profit Margin	-1113.37%	Rel Volume	0.94	Prev Close	17.33
Shortable	Yes	LT Debt/Eq	2.20	Earnings	Aug 07 AMC	Payout	-	Avg Volume	260.98K	Price	18.15
Recom	2.33	SMA20	-5.38%	SMA50	-4.67%	SMA200	-17.22%	Volume	244,217	Change	4.73%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-23	Upgrade	JP Morgan	Underweight → Neutral	$31 → $30
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy	$44
Sep-19-22	Resumed	H.C. Wainwright	Buy	$35
Sep-13-22	Downgrade	Truist	Buy → Hold	$50 → $28
Sep-01-22	Initiated	Raymond James	Outperform	$35
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Jun-22-21	Initiated	H.C. Wainwright	Buy	$43
May-21-21	Initiated	UBS	Neutral	$29
Mar-16-21	Upgrade	Truist	Hold → Buy
Mar-09-21	Downgrade	Wedbush	Outperform → Neutral
Mar-08-21	Downgrade	JP Morgan	Overweight → Underweight
Feb-11-21	Upgrade	JP Morgan	Underweight → Overweight	$40
Oct-27-20	Upgrade	Wedbush	Neutral → Outperform	$35
Oct-14-20	Upgrade	Guggenheim	Neutral → Buy	$36
Nov-08-19	Downgrade	Wedbush	Outperform → Neutral
Nov-08-19	Downgrade	SunTrust	Buy → Hold
Nov-08-19	Downgrade	JP Morgan	Overweight → Underweight	$109 → $17
Nov-08-19	Downgrade	Jefferies	Buy → Hold	$12

Show Previous Ratings

Sep-19-23 03:01PM	Insider Sell: Eric Loumeau Sells 6,000 Shares of AnaptysBio Inc (GuruFocus.com)
Sep-18-23 04:15PM	AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors (GlobeNewswire)
Sep-12-23 09:15AM	AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit (GlobeNewswire)
Aug-07-23 04:15PM	AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-23 01:34PM	AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer (GlobeNewswire) +15.13%
06:22AM	Loading…
Jul-04-23 06:22AM	Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested five years ago (Simply Wall St.)
May-30-23 04:15PM	AnaptysBio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-24-23 06:01AM	Need To Know: The Consensus Just Cut Its AnaptysBio, Inc. (NASDAQ:ANAB) Estimates For 2023 (Simply Wall St.)
May-22-23 01:44AM	4 big analyst picks: Norfolk Southern stock pops on 2 upgrades (Investing.com)
May-11-23 05:35PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update (GlobeNewswire)
May-04-23 09:55AM	Wall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should Know (Zacks)
May-02-23 09:15AM	AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
Apr-30-23 09:47AM	When Will AnaptysBio, Inc. (NASDAQ:ANAB) Breakeven? (Simply Wall St.)
Apr-27-23 10:02AM	Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
10:02AM	Loading…
Apr-26-23 10:02AM	Will AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-14-23 03:13AM	CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock? (Zacks)
Apr-06-23 04:15PM	AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors (GlobeNewswire)
Apr-03-23 07:14AM	Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-27-23 06:50PM	AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial (GlobeNewswire)
Mar-01-23 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-23 04:05PM	AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference (GlobeNewswire)
Jan-13-23 09:00AM	AnaptysBio Announces Stock Repurchase Plan (GlobeNewswire) +14.35%
Jan-05-23 04:05PM	AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies (GlobeNewswire)
Dec-22-22 09:33AM	The past five years for AnaptysBio (NASDAQ:ANAB) investors has not been profitable (Simply Wall St.)
Dec-02-22 09:00AM	AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer (GlobeNewswire)
Nov-21-22 01:56PM	AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-11-22 05:19AM	AnaptysBio Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-09-22 02:10PM	AnaptysBio to Participate in Upcoming November Investor Conferences (GlobeNewswire)
05:55PM	Loading…
Nov-08-22 05:55PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update (GlobeNewswire)
Oct-25-22 06:28AM	Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation (Simply Wall St.)
Oct-13-22 09:55AM	AnaptysBio, Inc. (ANAB) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +5.68%
Oct-06-22 11:02AM	GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal (Zacks)
Oct-05-22 11:31AM	AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial (Benzinga)
09:00AM	AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials (GlobeNewswire)
Sep-26-22 08:00AM	Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors (GlobeNewswire)
Sep-19-22 02:02PM	HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround (Benzinga)
Sep-14-22 06:14AM	New Forecasts: Here's What Analysts Think The Future Holds For AnaptysBio, Inc. (NASDAQ:ANAB) (Simply Wall St.)
Sep-12-22 11:18AM	AnaptysBio Sells Royalty Interest In Cancer Drug For $45M (Benzinga)
07:30AM	AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million (GlobeNewswire)
Sep-02-22 01:41PM	Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback (Benzinga)
Sep-01-22 09:58AM	AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication (Benzinga) +6.63%
Aug-31-22 04:15PM	AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire)
Aug-10-22 06:28AM	Analyst Forecasts Just Became More Bearish On AnaptysBio, Inc. (NASDAQ:ANAB) (Simply Wall St.)
Aug-08-22 05:35PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update (GlobeNewswire)
Aug-05-22 04:00PM	AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire) +6.65%
Jul-08-22 07:22AM	Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last? (Zacks)
Jun-24-22 06:31AM	AnaptysBio (NASDAQ:ANAB) shareholders are up 11% this past week, but still in the red over the last three years (Simply Wall St.)
Jun-02-22 04:05PM	AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-10-22 06:09AM	Downgrade: Here's How Analysts See AnaptysBio, Inc. (NASDAQ:ANAB) Performing In The Near Term (Simply Wall St.)
May-04-22 06:55PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:15PM	AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update (GlobeNewswire)
Apr-28-22 08:48AM	AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers (Benzinga) +5.47%
Apr-27-22 04:15PM	AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates (GlobeNewswire)
Apr-26-22 07:05AM	AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock? (Zacks)
Mar-21-22 04:15PM	AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer (GlobeNewswire)
Mar-15-22 11:35AM	AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal (Zacks) -6.72%
08:07AM	AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne (Benzinga)
Mar-14-22 04:20PM	AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne (GlobeNewswire)
Mar-09-22 05:09AM	Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth (Simply Wall St.) +6.07%
Mar-07-22 10:05AM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:50AM	AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update (GlobeNewswire)
Feb-17-22 03:02PM	AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Jan-21-22 10:49AM	BioDelivery (BDSI) Stock Up on Raised Guidance for 2021 (Zacks)
Jan-19-22 10:46AM	Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug (Zacks)
Jan-12-22 11:25AM	AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping Up (Insider Monkey)
Jan-08-22 06:13AM	AnaptysBio, Inc.'s (NASDAQ:ANAB) Intrinsic Value Is Potentially 23% Below Its Share Price (Simply Wall St.)
Jan-06-22 08:00AM	Recludix Pharma Announces Scientific Advisory Board (GlobeNewswire)
Jan-05-22 04:05PM	AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.92%
Dec-23-21 10:15AM	Anaptysbio Inc (ANAB) President, CEO Hamza Suria Sold $1.3 million of Shares (GuruFocus.com)
Nov-29-21 04:05PM	AnaptysBio Announces Appointment of Daniel Faga to Board of Directors (GlobeNewswire)
Nov-15-21 07:24PM	AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference (GlobeNewswire)
09:00AM	AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data (GlobeNewswire)
Nov-08-21 10:08AM	President And CEO Of Anaptysbio Trades $730K In Company Stock (Benzinga)
Nov-07-21 06:38AM	AnaptysBio, Inc.'s (NASDAQ:ANAB) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? (Simply Wall St.)
Nov-04-21 06:35PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates (GlobeNewswire)
Oct-27-21 10:49AM	AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping Up (Insider Monkey)
Oct-26-21 08:30AM	The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children (Benzinga) +6.83%
Oct-25-21 04:37PM	AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard (GlobeNewswire)
Oct-04-21 03:06PM	AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis (Benzinga)
Oct-02-21 12:00PM	AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis (GlobeNewswire)
Sep-09-21 04:05PM	AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-18-21 07:37AM	The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline (Benzinga)
06:59AM	AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication (Benzinga)
Aug-17-21 04:32PM	FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors (GlobeNewswire) +6.60%
Aug-09-21 05:35PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates (GlobeNewswire)
Aug-07-21 03:35AM	We're Interested To See How AnaptysBio (NASDAQ:ANAB) Uses Its Cash Hoard To Grow (Simply Wall St.)
Aug-05-21 10:50AM	10 Best Biotech Stocks to Buy According to Alan Fraziers Frazier Healthcare Partners (Insider Monkey)
Jul-26-21 07:40PM	Hedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too Early (Insider Monkey) -6.49%
May-27-21 04:15PM	AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-09-21 03:07AM	Forecast: Analysts Think AnaptysBio, Inc.'s (NASDAQ:ANAB) Business Prospects Have Improved Drastically (Simply Wall St.)
May-04-21 05:35PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates (GlobeNewswire)
Apr-28-21 12:33PM	Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline (Zacks)
Apr-23-21 10:31AM	European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe (GlobeNewswire)

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MULROY DENNIS	Chief Financial Officer	Sep 18	Sale	19.32	3,895	75,237	964	Sep 18 06:12 PM
LOUMEAU ERIC J	Chief Legal Officer	Sep 18	Sale	19.32	3,895	75,232	882	Sep 18 06:13 PM
Lizzul Paul F.	Chief Medical Officer	Sep 14	Sale	19.48	2,105	41,005	6,527	Sep 18 06:14 PM
LOUMEAU ERIC J	Chief Legal Officer	Sep 14	Sale	19.48	2,105	41,005	4,777	Sep 18 06:13 PM
MULROY DENNIS	Chief Financial Officer	Sep 14	Sale	19.48	2,105	41,005	4,859	Sep 18 06:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANAB | AnaptysBio Inc

Upgrade your FINVIZ experience